This paper is only available as a PDF. To read, Please Download here.
Abstract
From January 1994 through May 1995, Prudential HealthCare—North Texas prospectively
studied 299 member patients diagnosed with hypercholesterolemia for whom pharmacotherapy
with one of four 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also
known as statins, was prescribed. The purpose of this study was to measure the relative
cost-effectiveness (CE) of these drugs in a real-world setting. This study provides
information to assist decision makers in managed-care organizations (MCO) in making
formulary selections. The study used a prospective, randomized, balanced cohort design,
examining patients who had been prescribed initial therapy with a statin drug as monotherapy.
Costs (direct medical and indirect costs) and effectiveness (percent reduction in
low-density lipoprotein cholesterol levels) were based on approximately the first
6 months of initial therapy. Both the MCO and patient perspectives were considered.
In the base case, mean CE ratios were significantly lower for fluvastatin compared
with lovastatin, pravastatin, and simvastatin from both the managed-care perspective
and the patient perspective. Sensitivity analysis did not alter the CE conclusions,
even under conditions of varying cost structures. Although differences were found
in the effectiveness of lovastatin, pravastatin, and simvastatin measured in this
study versus efficacy measured for these drugs in controlled clinical trials, sensitivity
analysis suggests that these differences alone do not determine the superior CE of
fluvastatin. Finally, this study supports the idea that well-designed formularies
should consider drug CE (based on safety, effectiveness, and cost) and that integration
of the pharmacy benefit management with other medical management is essential. These
results provide evidence that fluvastatin may represent a more cost-effective formulary
choice among statin products used for initial monotherapy of hypercholesterolemia.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Serum cholesterol, lipoproteins, and the risk of coronary heart disease.Ann Intern Med. 1971; 74: 1-12
- Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,622 men.Lancet. 1986; 2: 933-939
- Plasma cholesterol concentration and death from coronary disease: 10 year results of the Whitehall Study.BMJ. 1986; 293: 306-307
- Cholesterol and coronary heart disease mortality: A 23-year follow-up study of 9902 men in Israel.Arteriosclerosis. 1990; 10: 512-519
- Short- and long-term association of serum cholesterol with mortality: The 25-year follow-up of the Finnish cohorts of the seven countries study.Am J Epidemiol. 1992; 135: 1251-1258
- Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?.JAMA. 1990; 263: 393-396
- Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged ≥ 62 years.Am J Cardiol. 1994; 73: 702-703
- Plasma cholesterol, coronary heart disease, and cancer in the Renfrow and Paisley survey.BMJ. 1989; 298: 920-924
- Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentrations, and diastolic blood pressure among black and white males followed for five years.Am Heart J. 1984; 108: 759-769
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.JAMA. 1984; 253: 2080-2086
- Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand. 1988; 223: 405-418
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).JAMA. 1993; 269: 3015-3023
- Regular physical exercise and low-fat diet: Effects on progression of coronary artery disease.Circulation. 1992; 86: 1-11
- Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of the NHLBI type II coronary intervention study.Circulation. 1984; 69: 313-324
- Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA. 1987; 257: 3233-3240
- Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP).Circulation. 1994; 89: 975-990
- Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- Mechanism of action and biological profile of HMG-CoA reductase inhibitors: A new therapeutic alternative.Drugs. 1988; 36 (Suppl 3): 72-82
- HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.NEJM. 1988; 319: 24-33
- Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety.Am J Med. 1994; 96 (Suppl 6A): 6A 415-6A 445
- Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.Arch Intern Med. 1991; 151: 43-49
- Effects of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors.Am J Cardiol. 1993; 72: 1031-1037
- Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia.Clin Ther. 1992; 14: 708-717
- Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings?.NEJM. 1995; 332: 1125-1131
- Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.Ann Pharmacother. 1995; 29: 743-759
- Management of primary hyperlipidemia.NEJM. 1995; 332: 1491-1498
- Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacological management.JAMA. 1990; 264: 3025-3033
- Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.JAMA. 1991; 265: 1145-1151
- An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.Am J Cardiol. 1991; 67: 789-792
- Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.Clin Ther. 1994; 16: 1052-1067
- Replacing lovastatin with pravastatin: Effect on serum lipids and costs.Am J Health Syst Pharm. 1995; 52: 1078-1082
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.Am J Cardiol. 1994; 73 (Suppl): 3D-11D
- Single factor analysis of variance by ranks.in: Biostatistical Analysis. Prentice-Hall, Inc, Englewood Cliffs, NJ1974: 139-142
- Confidence intervals for differences between means.in: Biostatistical Analysis. Prentice Hall, Inc, Englewood Cliffs, NJ1974: 155-156
- Cost determination and analysis.in: Bootman JL Townsend RJ McGhan WF Principles of Pharmacoeconomics. Harvey Whitney Books, New York1994: 35-49
- Critical assessment of economic evaluation.in: House J Methods for the Economic Evaluation of Health Care Programmers. Oxford University Press, New York1994: 26-27
- Economic analysis of health care technology: A report of principles.Ann Intern Med. 1995; 122: 61-70
- Guidelines for the clinical and economic evaluation of health care technologies.Soc Sci Med. 1986; 22: 393-408
- Cost-effectiveness analysis.in: Bootman JL Townsend RJ McGhan WF Principles of Pharmacoeconomics. Harvey Whitney Books, New York1991: 72-101
- Krischner CG Burkett RC Kotowicz GM Physicians' Current Procedural Terminology (CPT 1995). American Medical Association, Chicago, Ill1994
- Medical Prevailing Healthcare Charges System. Health Insurance Association of America, Washington, DC1995
- Vital Statistics, 1994. Bureau of Labor Statistics, Washington, DC1994
- Economic analysis of health technologies and programmes: A Spanish proposal for methodological standardization.PharmacoEconomics. 1995; 8: 245-252
- Use of confidence intervals and sample size calculations in health economic studies.Ann Pharmacother. 1995; 29: 719-724
- The cholesterol population model: US population requirements for treatment of hypercholesterolemia.Am J Managed Care. 1996; 2: 1362-1370
- Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.Am J Cardiol. 1995; 76 (FLUENT Study Group) (Suppl 2): 37A-40A
- Efficacy and safety of fluvastatin, a new HMG-CoA reductase inhibitor, in elderly hypercholesterolemic women.Drugs. 1994; 47 (Suppl): 59-63
- Fluvastatin reduces levels of plasma apo B-containing particles and increases those of Lp(a)-1.Am J Med. 1994; 96 (European Fluvastatin Study Group) (Suppl): 325-365
- Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.Clin Ther. 1992; 14: 276-291
- Treatment of primary hypercholesterolemia: Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study.J Intern Med. 1993; 234: 77-82
- Dose-response of simvastatin in primary hypercholesterolemia.J Cardiovasc Pharmacol. 1994; 24: 941-949
- A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.Circulation. 1995; 92 (Kupio Atherosclerosis Prevention Study (KAPS)): 1758-1764
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
